Sildenafil 100mg Hexal: Uses and Indications
[DOI] [PMC free article] [PubMed] [Google Scholar] 40.Volkmann ER, Tashkin DP, Sim M, et al.
| Guidance Aspect | Recommendation | Potential Risks | Additional Advice |
|---|---|---|---|
| Take on an empty stomach | Preferably | Delayed absorption if high-fat meal | Avoid heavy meals before intake |
| Avoid alcohol | Yes | Increased chance of side effects | Limit or avoid alcohol |
| Physical activity | Adequate rest before sex | Dizziness or hypotension | Be cautious with activities |
| Follow prescribed dose | Strictly adhere | Overdose risk (e.g., priapism) | Consult doctor if in doubt |
Cyclophosphamide for systemic sclerosis-related interstitial lung disease: a comparison of scleroderma lung study I and II. [DOI] [PMC free article] [PubMed] [Google Scholar] 41.Volkmann ER, Tashkin D. Roth M, LeClair H, et al. Mycophenolate mofetil and cyclophosphamide improve health-related quality of life in patients with systemic sclerosis who participated in SLS II. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Efficacy and safety of tocilizumab for the treatment of systemic sclerosis: results from a phase 3 randomized controlled trial.
Possible side effects of TOURNES 100mg
[DOI] [PMC free article] [PubMed] [Google Scholar] Management of systemic sclerosis-related skin disease: a review of existing and experimental therapeutic approaches. 8.Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Scleroderma trials study G. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
2.2. Interstitial lung disease
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. [DOI] [PMC free article] [PubMed] [Google Scholar] 12.Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. [DOI] [PMC free article] [PubMed] [Google Scholar]; • This landmark RCT demonstrated that MMF was not only as effective as CYC at improving lung function and radiographic fibrosis in ILD, but was safer and better tolerated than CYC. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials.
1.1. Determining when therapy is indicated
[DOI] [PMC free article] [PubMed] [Google Scholar] 14.Volkmann ER, Tashkin DP, Li N, et al. Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. [DOI] [PMC free article] [PubMed] [Google Scholar] 15.Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. [DOI] [PubMed] [Google Scholar]; • This was the first large, RCT to evaluate the safety and efficacy of HSCT in SSc and demonstrated improved long-term mortality in dsSSc patients randomized to HSCT compared with CYC. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.
- Sildenafil 100mg Hexal has been tested for safety and efficacy.
- Consult your doctor if you have a history of stroke.
- Avoid combining with recreational drugs.
- It can cause side effects like nasal congestion.
- Proper hydration helps reduce side effects.
[DOI] [PMC free article] [PubMed] [Google Scholar] 45.Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. [DOI] [PMC free article] [PubMed] [Google Scholar] 47.Nihtyanova SI, Brough GM, Black CM, et al. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 25mg | 360 + 10 Pills | 213.68€ 203.50€ | |
| Kamagra Soft Tabs | 100mg | 120 + 6 Pills | 311.78€ 296.93€ | |
| Viagra Generic | 150mg | 90 + 6 Pills | 147.18€ 140.17€ | |
| Viagra Generic | 100mg | 20 Pills | 45.58€ 43.41€ | |
| Kamagra Polo | 100mg | 20 Pills | 83.56€ 79.58€ | |
| Kamagra Oral Jelly | 100mg | 90 + 8 Sachets | 303.56€ 289.10€ | |
| Kamagra Polo | 100mg | 272 + 12 Pills | 622.94€ 593.28€ | |
| Viagra Generic | 150mg | 10 Pills | 36.73€ 34.98€ | |
| Kamagra Soft Tabs | 100mg | 12 Pills | 57.55€ 54.81€ | |
| Viagra Generic | 200mg | 360 + 10 Pills | 481.98€ 459.03€ | |
| Viagra Generic | 50mg | 90 + 6 Pills | 107.37€ 102.26€ | |
| Viagra Generic | 50mg | 180 + 8 Pills | 158.82€ 151.26€ | |
| Kamagra | 100mg | 360 + 6 Pills | 839.95€ 799.95€ | |
| Kamagra Oral Jelly | 100mg | 110 + 9 Sachets | 334.87€ 318.92€ | |
| Viagra Generic | 50mg | 120 + 6 Pills | 129.64€ 123.47€ |
On-demand sildenafil as a treatment for Raynaud phenomenon: a series of n-of-1 trials.
Article highlights.
Z McMahan is supported by the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases via grant K23 AR071473, the Scleroderma Research Foundation and the Jerome L Greene Foundation. ER Volkmann is supported by National Institutes of Health/The National Heart, Lung, and Blood Institute via grant K23 HL150237-01 and the Rheumatology Research Foundation. One referee has received speaker’s fees, travel grants, research funding, or compensation for consultancies or board memberships from Abbvie, Actelion, Baxalta/Shire, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Chugai, Genzyme, Gilead Biosciences, Hexal/Sandoz, Janssen-Cilag, Merck Sharp and Dohme, Novartis, Pfizer, Roche, Sanofi Pasteur and UCB Pharma. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose. ER Volkmann has received grant support from Corbus Pharmaceuticals and Forbius, and consulting fees from Forbius and Boehringer Ingelheim.
2.3. Raynaud phenomenon
ZH McMahan has received salary support from Corbus Pharmaceuticals for her work as a subinvestigator on the Lenabasum study. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers. Treatment algorithms for systemic sclerosis according to experts. Emerging targets of disease-modifying therapy for systemic sclerosis.
2.1. Cutaneous sclerosis
[DOI] [PMC free article] [PubMed] [Google Scholar] 4.Peoples C, Medsger TA Jr., Lucas M, et al. Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes. [DOI] [PMC free article] [PubMed] [Google Scholar] February;34(1):1–15;v. [DOI] [PubMed] [Google Scholar] 6.Sierra-Sepulveda A, Esquinca-Gonzalez A, Benavides-Suarez SA, et al. Systemic sclerosis pathogenesis and emerging therapies, beyond the fibroblast. Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study.
About this chapter
[DOI] [PubMed] [Google Scholar] 37.Goldin JG, Kim GHJ, Tseng CH, et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the scleroderma lung study II. [DOI] [PMC free article] [PubMed] [Google Scholar] 38.Khanna D, Yan X, Tashkin DP, et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Sep-Oct;35(Suppl 106(4)):151–158.
All you need to know about TOURNES 100mg .
Myeloablative autologous stem-cell transplantation for severe scleroderma. [DOI] [PMC free article] [PubMed] [Google Scholar]; • This was the second large, RCT to evaluate the safety and efficacy of HSCT in SSc and also demonstrated improved long-term mortality in dsSSc patients randomized to HSCT compared with CYC. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). [DOI] [PMC free article] [PubMed] [Google Scholar] 19.Khanna D, Spino C, Johnson S, et al. Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial.
2.5. Gastrointestinal disease
[DOI] [PMC free article] [PubMed] [Google Scholar] 20.Gonzalez EG, Selvi E, Balistreri E, et al. Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Safety and efficacy of lenabasum (JBT-101) in diffuse cutaneous systemic sclerosis subjects treated for one year in 20mg sildenafil an open-label extension of trial JBT101-SSC-001. The American college of rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis. [DOI] [PMC free article] [PubMed] [Google Scholar] 23.R Dn S, Bloom B, White B, et al.
Expert opinion:
Baseline subject demographics and disease characteristics in a phase 3 study of safety and efficacy of lenabasum in diffuse cutaneous systemic sclerosis. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. Nintedanib for systemic sclerosis-associated interstitial lung disease. [DOI] [PubMed] [Google Scholar]; • This was the largest RCT ever conducted in SSc and demonstrated that treatment with nintedanib slows the rate of decline of lung function in patients with SSc-ILD compared with placebo. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study.
- Do not drive or operate machinery after taking Sildenafil.
- It may cause temporary vision disturbances.
- Notify your doctor of any heart problems.
- Take the medication with water, not with a heavy meal.
- Keep out of reach of children.
Randomized placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.
Mode of Action TOURNES 100mg
A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopatho-logical study. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis.
Download citation
Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Severe restrictive lung disease in systemic sclerosis. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. October;69(10):1809–1815. [DOI] [PubMed] [Google Scholar] 35.Volkmann ER, Tashkin DP, Kuwana M, et al.
Authors and Affiliations
Progression of Interstitial Lung Disease in Systemic Sclerosis: the Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. December;71(12):2059–2067. [DOI] [PMC free article] [PubMed] [Google Scholar] 36.Fischer A, Strek ME, Cottin V, et al. Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland connective tissue disease-associated interstitial lung disease summit: a multidisciplinary approach to address challenges and opportunities. February;71(2):182–195.